Skip to main content

Vidarabine

ADVERTISEMENT
Identification
Molecular formula
C10H13N5O4
CAS number
5536-17-4
IUPAC name
2-(hydroxymethyl)-5-[6-[(1-methyl-2-phenyl-ethyl)amino]purin-9-yl]tetrahydrofuran-3,4-diol
State
State

Vidarabine is typically a solid at room temperature, maintaining its stability when stored properly.

Melting point (Celsius)
206.00
Melting point (Kelvin)
479.15
Boiling point (Celsius)
191.40
Boiling point (Kelvin)
464.55
General information
Molecular weight
267.24g/mol
Molar mass
267.2690g/mol
Density
1.0100g/cm3
Appearence

Vidarabine generally appears as a white to off-white crystalline powder. The compound is sensitive to light and should be handled with care to prevent degradation.

Comment on solubility

Solubility of 2-(hydroxymethyl)-5-[6-[(1-methyl-2-phenyl-ethyl)amino]purin-9-yl]tetrahydrofuran-3,4-diol

The solubility of the compound 2-(hydroxymethyl)-5-[6-[(1-methyl-2-phenyl-ethyl)amino]purin-9-yl]tetrahydrofuran-3,4-diol, with the chemical formula C10H13N5O4, can be influenced by various factors. Below are key considerations regarding its solubility:

  • Solvent Interaction: Solubility often depends on the nature of the solvent used. Polar solvents like water may enhance the solubility due to hydrogen bonding capabilities.
  • Functional Groups: The presence of hydroxyl (-OH) and amino (-NH) groups typically increases a compound's solubility in polar solvents.
  • pH Sensitivity: The solubility of many organic compounds can change with pH due to ionization of functional groups.
  • Structural Complexity: The intricate structure of this compound suggests that intermolecular forces could be significant, affecting the solubility profile.

In conclusion, while the exact solubility characteristics of this compound require empirical investigation, factors such as solvent type, functional group interactions, pH, and structural complexity play pivotal roles in determining its solubility.

Interesting facts

Interesting Facts about 2-(Hydroxymethyl)-5-[6-[(1-methyl-2-phenyl-ethyl)amino]purin-9-yl]tetrahydrofuran-3,4-diol

This compound, often referred to for its complex structure and potential applications in pharmaceuticals, exhibits intriguing characteristics that are worth exploring:

  • Biochemical Relevance: The structure of this compound features a purine base, a key component of nucleic acids, suggesting its relevance in biochemical processes such as DNA and RNA synthesis.
  • Pharmacological Potential: Compounds with similar structures are often investigated for their potential in drug development, particularly in targeting specific pathways involved in cellular signaling and mechanisms of action.
  • Structural Diversity: The tetrahydrofuran ring in its structure provides interesting geometric and electronic properties, which can affect the interactions of the compound with biological macromolecules.
  • Modification Opportunities: The presence of various functional groups opens avenues for chemical modifications, which can lead to the design of more effective therapeutics.
  • Research Interest: Studies have shown that analogs of this compound may have anti-cancer, anti-viral, and anti-inflammatory properties, making it a subject of ongoing research in medicinal chemistry.

In summary, 2-(hydroxymethyl)-5-[6-[(1-methyl-2-phenyl-ethyl)amino]purin-9-yl]tetrahydrofuran-3,4-diol is not just a fascinating chemical entity but also embodies the potential to contribute significantly to biological sciences and pharmaceutical applications. As research progresses, we may uncover more about its unique properties and uses.

Synonyms
R-PIA
CHEMBL274022
L-PIA
S-PIA
l-Phenylisopropyladenosine
(R)-(Phenylisopropyl)adenosine
R(-)-PIA
(-)-PIA
r-phenylisopropyladenosine
REGID_for_CID_5022
ChEMBL_20163
MLS000859990
N(6)-D-phenylisopropyladenosine
SCHEMBL14829806
(R)-N-(phenylisopropyl)adenosine
2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
CHEBI:192091
HMS2232M21
HMS3371L16
HMS3373F22
(R)-N(6)-phenylisopropyladenosine
N(6)-(R)-phenylisopropyladenosine
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-((1-phenylpropan-2-yl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-{[(2R)-1-phenylpropan-2-yl]amino}-9H-purin-9-yl)oxolane-3,4-diol
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-{6-[(1-phenylpropan-2-yl)amino]-9H-purin-9-yl}oxolane-3,4-diol
(R)-2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
(R-PIa) 2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
(S)-2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
D-2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
L-2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol
R-N6-(2-phenylisopropyl) adenosine
()-N6-(2-Phenylisopropyl)adenosine
BDBM50006730
L-2-N(6)-(phenylisopropyl)adenosine
N(6)-(L-2-phenylisopropyl)adenosine
(-)-N-(alpha-methylphenethyl)adenosine
(-)-N(6)-(2-phenylisopropyl)adenosine
(R)-(-)-N(6)-phenylisopropyladenosine
(R)-N(6)-(2-phenylisopropyl)adenosine
n-[(2r)-1-phenylpropan-2-yl]adenosine
R-(-)-N(6)-2-phenylisopropyladenosine
SMR000326849
R(-)-N(6)-(2-phenylisopropyl)adenosine
DB-049309
(r)-n(6)-(1-methyl-2-phenylethyl)adenosine
N(6)-[(R)-1-methyl-2-phenylethyl]adenosine
L000522
2-(hydroxymethyl)-5-{6-[(1-phenylpropan-2-yl)amino]-9H-purin-9-yl}oxolane-3,4-diol